Published Date: 08 Mar 2023
Over the past 50 years, there has been much speculation about the quality of Wolfgang Amadeus Mozart's music. The report indicates that listening to Mozart's sonata KV448 in epilepsy patients reduces symptoms is interesting...
Read Full NewsBy analyzing data from three clinical trials treating children with the brain tumor medulloblastoma, scientists at St. Jude Children's Research Hospital have designed an approach to safely reduce therapy, thereby lowering ...
Radiotherapy can be safely omitted as a treatment for many breast cancer patients who have had a mastectomy and are taking anti-cancer drugs, a study shows.
People diagnosed with advanced breast cancer in 2025 can expect to live for an extra six or seven months, compared to the average survival time for patients diagnosed in 2011, according to a major study of patient data in ...
1.
Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer
2.
Squeezing through tiny blood vessels may trigger melanoma cells to spread
3.
Taking the "Boob Bus"; Reluctance to Grant Prior Authorization; Alcohol's Carcinogenic Potential?
4.
Unified Neuro/Psych Residency Program: New Proposal.
5.
Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's Lymphoma
1.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
2.
Engineering the Future of Oncology with CAR- Natural Killer Cell Design & Therapeutics
3.
Neuroendocrine Tumors: Mechanisms of Mortality, Associated Conditions
4.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
5.
Cancer Vaccines In India: The Latest Hope In The Fight Against Disease
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
3.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
4.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation